ArticleInternational journal of nanomedicine2017
Spermidine-mediated poly(lactic-
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 85 citations in OpenAlex.
- Hierarchical microtopology and phase-specific delivery functionally restore ultralong nerve continuity across species.Science advances · 2026Article
- MXene quantum dot polymer nanocomposites as smart platforms for targeted drug delivery and multifunctional biomedical applications: an updated review.Discover nano · 2026Review
- Intranasal hybrid nanoparticles encapsulating rizatriptan enhance antimigraine efficacy in an optogenetic spreading depression model.International journal of pharmaceutics · 2026Article
- The role of spermidine in plants and humans: a pathway from climate change adaptation to health benefits.NPJ science of food · 2026Review
- Article
- Delivery strategies to improve the pharmacological efficacy of NRF2 modulators: a review.RSC medicinal chemistry · 2025Review
- Polymeric microneedle advancements in macromolecule drug delivery: current trends, challenges, and future perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Therapeutic Approach Based on Nanotechnology with Chitosan-Coated Zein Nanoparticles Containing Quercetin Against ResistantPharmaceutics · 2025Article
- Inhalable Nanotechnology-Based Drug Delivery Systems for the Treatment of Inflammatory Lung Diseases.Pharmaceutics · 2025Review
- Aptamer-engaged nanotherapeutics against SARS-CoV-2.Discover nano · 2025Review
- Formononetin-Loaded PLGA Large Porous Microparticles via Intratracheal Instillation for Bleomycin-Induced Pulmonary Fibrosis Treatment.AAPS PharmSciTech · 2025Article
- Network Pharmacology and Experimental Validation Reveal Ganodermanontriol Modulates Pneumonia via TNF/NF-κB/MAPKs Signaling Pathway.Food science & nutrition · 2025Article
- Exploring TGF-β signaling in benign prostatic hyperplasia: from cellular senescence to fibrosis and therapeutic implications.Biogerontology · 2025Review
- Mendelian randomization study of serum uric acid levels and urate-lowering drugs on pulmonary arterial hypertension outcomes.Scientific reports · 2025Article
- Improved lung nodule segmentation with a squeeze excitation dilated attention based residual UNet.Scientific reports · 2025Article
- Advancing Small Nucleic Acid Drug Delivery: From Stability Challenges to Novel Therapeutic Applications.Current drug delivery · 2025Review
- Mannosamine-Engineered Nanoparticles for Precision Rifapentine Delivery to Macrophages: Advancing Targeted Therapy Against Mycobacterium Tuberculosis.Drug design, development and therapy · 2025Article
- Revolutionizing the Treatment of Idiopathic Pulmonary Fibrosis: From Conventional Therapies to Advanced Drug Delivery Systems.AAPS PharmSciTech · 2024Review
- Emerging delivery approaches for targeted pulmonary fibrosis treatment.Advanced drug delivery reviews · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiopathic pulmonary fibrosis is a progressive, fatal lung disease with poor survival. The advances made in deciphering this disease have led to the approval of different antifibrotic molecules, such as pirfenidone and nintedanib. An increasing number of studies with particles (liposomes, nanoparticles [NPs], microspheres, nanopolymersomes, and nanoliposomes) modified with different functional groups have demonstrated improvement in lung-targeted drug delivery. In the present study, we prepared, characterized, and evaluated spermidine (Spd)-modified poly(lactic-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.